Affimed (AFMD)
(Delayed Data from NSDQ)
$5.14 USD
+0.08 (1.58%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $5.11 -0.03 (-0.58%) 6:24 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
AFMD 5.14 +0.08(1.58%)
Will AFMD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AFMD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AFMD
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Tops Revenue Estimates
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
AFMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
Other News for AFMD
Affimed Shareholders Approve Key Resolutions
Affimed (AFMD) Gets a Buy from Truist Financial
Analysts Offer Insights on Healthcare Companies: R1 RCM (RCM), Affimed (AFMD) and Nurix Therapeutics (NRIX)
Affimed (AFMD) Receives a Buy from Truist Financial
Affimed price target raised by $10 at Laidlaw, here's why